Provectus Biopharmaceuticals (PVCT) Cash & Equivalents (2010 - 2026)
Provectus Biopharmaceuticals' Cash & Equivalents was $1.16 million in Q2 2026, up 177.8% from $416,471 a year earlier.
Powered by 
Analysis
Provectus Biopharmaceuticals (PVCT) Cash & Equivalents (2010 - 2026) Analysis & Trends
At the end of FY2025, Cash & Equivalents at Provectus Biopharmaceuticals came in at $251,291, down 48.7% from FY2024.
- Cash & Equivalents has now declined for four consecutive years, though with a five-year compound annual growth rate of 20.9% (FY2020 to FY2025).
- In earlier years, Cash & Equivalents was $489,726 in FY2024 (-52.3%), $1.03 million in FY2023 (-28.3%), $1.43 million in FY2022 (-53.9%) and $3.11 million in FY2021.
- The Q2 2026 figure marks the highest quarterly Cash & Equivalents since Q3 2023.
- Compared with a year earlier, Cash & Equivalents was higher in 1 of the last seven quarters, with an average decline of 19.4%.
- The best year-over-year quarter for Cash & Equivalents over five years was Q1 2022 (growth of 609.3%); the worst was Q3 2025 (a decline of 88.2%).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,230.11 Bn | 1,198.70 Bn | 19.71 Bn | 8.95 Bn |
| 2 | Johnson & Johnson | 644.39 Bn | 564.25 Bn | 17.30 Bn | 16.91 Bn |
| 3 | AbbVie | 503.52 Bn | 476.68 Bn | 12.70 Bn | 6.57 Bn |
| 4 | Merck | 363.29 Bn | 317.72 Bn | 12.21 Bn | 6.85 Bn |
| 5 | Novartis Ag | 298.23 Bn | 262.62 Bn | 11.24 Bn | 7.62 Bn |
| 6 | Astrazeneca | 267.53 Bn | 241.29 Bn | 12.86 Bn | 4.90 Bn |
| 7 | Amgen | 241.80 Bn | 197.20 Bn | 7.24 Bn | 13.99 Bn |
| 8 | Gilead Sciences | 195.07 Bn | 169.19 Bn | 6.22 Bn | 3.18 Bn |
| 9 | Pfizer | 173.33 Bn | 120.28 Bn | 10.94 Bn | 976.00 Mn |
| 10 | Provectus Biopharmaceuticals | 21.01 Mn | 19.10 Mn | - | 1.16 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.16 Mn |
| Dec 31, 2025 | 251,291.00 |
| Sep 30, 2025 | 72,479.00 |
| Jun 30, 2025 | 416,471.00 |
| Mar 31, 2025 | 469,454.00 |
| Dec 31, 2024 | 489,726.00 |
| Sep 30, 2024 | 614,189.00 |
| Jun 30, 2024 | 589,283.00 |
| Mar 31, 2024 | 762,752.00 |
| Dec 31, 2023 | 1.03 Mn |
| Sep 30, 2023 | 1.41 Mn |
| Jun 30, 2023 | 1.36 Mn |
| Mar 31, 2023 | 1.32 Mn |
| Dec 31, 2022 | 1.43 Mn |
| Sep 30, 2022 | 1.71 Mn |
| Jun 30, 2022 | 2.03 Mn |
| Mar 31, 2022 | 2.48 Mn |
| Dec 31, 2021 | 3.11 Mn |
| Sep 30, 2021 | 254,083.00 |
| Jun 30, 2021 | 47,407.00 |
API Access
Provectus Biopharmaceuticals Cash & Equivalents API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=PVCT&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "cash-and-equivalents", "ticker": "PVCT", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=PVCT&period=max&api_key=YOUR_API_KEY");
const data = await res.json();